Clinical Trial

TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment

Study acronym: TASK-01-RW
Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective, non-interventional, observational study evaluating the efficacy and immune microenvironment changes in Patients with Advanced Hepatocellular Carcinoma treated with TACE Combined with PD-1 Inhibitor.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-27; most recent amendment 2025-08-14.
Status change: Not Yet Recruiting → Recruiting 2025-08-10
Trial Details
NCT Number NCT07100405
Lead Sponsor Fudan University
Conditions Hepatocellular Carcinoma
Enrollment 50 participants
Start Date 2025-08-15
Primary Completion 2027-08-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-17